US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arin Tactical Tail Risk ETF

90.09

+0.00220.00%

Volume:2.02K

Turnover:181.94K

Market Cap:55.78M

PE:- -

High:90.16

Open:90.16

Low:90.09

Close:90.09

52wk High:90.16

52wk Low:45.10

Shares:619.15K

Float Shares:619.15K

Volume Ratio:1.91

T/O Rate:0.33%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

1 Stock Up by 63% This Year That Could Double, According to Wall Street

Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ATTR"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ATTR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATTR\",,,,,undefined,":{"symbol":"ATTR","market":"US","secType":"STK","nameCN":"Arin Tactical Tail Risk ETF","latestPrice":90.0872,"timestamp":1762549200000,"preClose":90.085,"halted":0,"volume":2018,"delay":0,"floatShares":619146,"shares":619146,"eps":0,"marketStatus":"Market Closed","change":0.0022,"latestTime":"11-07 16:00:00 EST","open":90.16,"high":90.16,"low":90.0872,"amount":181942.7791,"amplitude":0.000808,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1762765200000},"marketStatusCode":7,"adr":0,"exchange":"CBOE","adjPreClose":90.085,"sharesOutstanding":619146,"nav":90.11,"aum":55791246.06,"bidAskSpread":0,"volumeRatio":1.9117087452423864},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATTR\",,,,,undefined,":{"symbol":"ATTR","floatShares":619146,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.9117087452423864,"shares":619146,"dividePrice":0,"high":90.16,"amplitude":0.000808,"preClose":90.085,"low":90.0872,"week52Low":45.1,"pbRate":"--","week52High":90.16,"institutionHeld":0,"latestPrice":90.0872,"eps":0,"divideRate":0,"volume":2018,"delay":0,"ttmEps":0,"open":90.16,"prevYearClose":89.97,"prevWeekClose":89.965,"prevMonthClose":89.965,"prevQuarterClose":89.97,"fiveDayClose":89.965},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATTR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATTR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ATTR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATTR\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2580029008","title":"BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2580029008","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580029008?lang=en_us&edition=fundamental","pubTime":"2025-11-03 20:30","pubTimestamp":1762173000,"startTime":"0","endTime":"0","summary":"PALO ALTO, Calif., Nov.  03, 2025  (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/03/3179150/0/en/BridgeBio-to-Present-Data-from-the-Overall-ATTR-CM-Variant-and-V142I-V122I-Populations-from-ATTRibute-CM-at-the-AHA-Scientific-Sessions-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATTR","CM","BK4207"],"gpt_icon":0},{"id":"2578648062","title":"Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)","url":"https://stock-news.laohu8.com/highlight/detail?id=2578648062","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578648062?lang=en_us&edition=fundamental","pubTime":"2025-10-27 19:30","pubTimestamp":1761564600,"startTime":"0","endTime":"0","summary":"Conference call today at 8:30 a.m. ETCAMBRIDGE, Mass., Oct.  27, 2025  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutio","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/27/3174462/0/en/Intellia-Therapeutics-Provides-Update-on-MAGNITUDE-Clinical-Trials-of-Nexiguran-Ziclumeran-nex-z.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NTLA","BK4585","BK4611","LU1861558580.USD","BK4183","ODD","IE0009354923.USD","CRSP","ATTR","LU1861559042.SGD","BK4588","BK4556","BK4535"],"gpt_icon":0},{"id":"2573924963","title":"1 Stock Up by 63% This Year That Could Double, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2573924963","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573924963?lang=en_us&edition=fundamental","pubTime":"2025-10-07 21:45","pubTimestamp":1759844700,"startTime":"0","endTime":"0","summary":"Some math suggests that even Wall Street is lowballing the stock's potential.","market":"nz","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F835831%2Fscientist-altering-dna-genome-project.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F835831%2Fscientist-altering-dna-genome-project.jpg&op=resize&w=165&h=104"],"rights":{"source":"fool_stock","url":"https://www.fool.com/investing/2025/10/07/1-stock-up-by-63-this-year-that-could-double/","rn_cache_url":null,"customStyle":"","selectors":".main-contain, #article-page","filters":"#sticky-wrapper, .navigation, .article-page-end, .foot, .author-tagline, .author-inline, .footer, .soc-share, .wysiwyg, .related-content","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/10/07/1-stock-up-by-63-this-year-that-could-double/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["IE00B19Z6F94.USD","ATTR","LU1169589451.USD","IE0034390439.USD","LU1169590202.USD","HAE","LU0205194284.USD","LU0106261612.USD","BK4198","LU0205193047.USD","LU0012050646.USD","IE00BLDYK493.USD","IE00B64QTZ34.USD"],"gpt_icon":0},{"id":"2570557828","title":"Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM","url":"https://stock-news.laohu8.com/highlight/detail?id=2570557828","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570557828?lang=en_us&edition=fundamental","pubTime":"2025-09-28 23:15","pubTimestamp":1759072500,"startTime":"0","endTime":"0","summary":"- By Month 1, numerically fewer cumulative events were observed with acoramidis compared to placebo - Acoramidis significantly reduced the  cumulative risk of CVM or recurrent CVH through Month 30 ver","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/28/3157362/0/en/Acoramidis-Begins-to-Reduce-Cumulative-Cardiovascular-Outcomes-Within-the-First-Month-of-Treatment-in-Patients-with-ATTR-CM.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CM","CSII","ATTR","BK4585","CVM","BBIO","BK4082","LU2308191902.HKD","BK4516","BK4129","ACM","BK4588","LU0124676726.USD","BK4188","BK4207","BK4139","ASM","LU0689626769.HKD","BK4505"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ATTR\",params:#limit:6,delay:false,,,undefined,":[]}}